Therapeutic antibodies, targeting the SARS-CoV-2 spike N-terminal domain, protect lethally infected K18-hACE2 mice
Tal Noy-Porat, Adva Mechaly, Yinon Levy, Efi Makdasi, Ron Alcalay, David Gur, Moshe Aftalion, Reut Falach, Shani Leviatan Ben‐Arye, Shirley Lazar, Ayelet Zauberman, Eyal Epstein, Theodor Chitlaru, Shay Weiss, Hagit Achdout, Jonathan D. Edgeworth, Raghavendra Kikkeri, Hai Yu, Xi Chen, Shmuel Yitzhaki, Shmuel C. Shapira, Vered Padler‐Karavani, Ohad Mazor, Ronit Rosenfeld
Abstract
-glycan epitope recognition, suggesting alternative viral cellular portals. Two selected mAbs demonstrated full protection of K18-hACE2 transgenic mice when administered at low doses and late post-exposure, demonstrating the high potential of the mAbs for therapy of SARS-CoV-2 infection.
Topics & Concepts
EpitopeMonoclonal antibodyVirologyAntibodyNeutralizationBiologyRecombinant DNANeutralizing antibodyEpitope mappingGlycanVirusGlycoproteinImmunologyMolecular biologyGeneGeneticsSARS-CoV-2 and COVID-19 ResearchVirus-based gene therapy researchMonoclonal and Polyclonal Antibodies Research